What Is Dulaglutide?

1. The Short Answer

Dulaglutide is the active ingredient in Trulicity, a prescription GLP-1 receptor agonist injection from Lilly. The current DailyMed Trulicity label was updated on March 12, 2026, and identifies the product as Trulicity, dulaglutide injection, for subcutaneous use.

The current U.S. label context is specific. DailyMed says Trulicity is indicated with diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. The same label also includes reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.

The official Trulicity site uses similar consumer-facing language: Trulicity is for adults and children 10 years and older with type 2 diabetes to improve blood sugar, and it is also used in adults with type 2 diabetes to reduce the risk of major cardiovascular events in people with heart disease or multiple cardiovascular risk factors.

That does not make dulaglutide a general synonym for every GLP-1 medicine. It is one active ingredient in one brand family.

2. Dulaglutide vs Trulicity

Dulaglutide is the molecule. Trulicity is the brand. Keeping that distinction clear prevents a lot of search-result confusion.

The relationship looks like this:

Those layers are not interchangeable. “Dulaglutide” does not tell you the full brand, patient population, warnings, label history, insurance status, or clinical fit. “Trulicity” tells you the brand context, but the active ingredient is still dulaglutide.

This is the same naming pattern used across many GLP-1 searches. Liraglutide is the active ingredient associated with Victoza and Saxenda. Semaglutide is the active ingredient associated with Ozempic, Wegovy, and Rybelsus. Tirzepatide is the active ingredient associated with Mounjaro and Zepbound.

3. Why Dulaglutide Is Part of the GLP-1 Category

Dulaglutide belongs in the GLP-1 category because the current Trulicity label describes it as a glucagon-like peptide-1 receptor agonist. For broader terminology, see What Is a GLP-1?.

The category wording is helpful, but it can also be too broad. “GLP-1” can mean the natural hormone, the receptor pathway, the medication class, a brand family, or a loose public shorthand for newer metabolic medicines. Dulaglutide is more specific than that shorthand.

NCBI Bookshelf’s GLP-1 receptor agonist class overview places dulaglutide alongside other GLP-1 receptor agonists and describes dulaglutide as a once-weekly GLP-1 receptor agonist in class comparisons. The same source distinguishes tirzepatide because current tirzepatide labels use both GIP and GLP-1 receptor language.

For readers, the clean takeaway is simple: dulaglutide is a GLP-1 receptor agonist molecule associated with Trulicity. It is not a semaglutide product, not a liraglutide product, and not a tirzepatide product.

4. The U.S. Label Context: Type 2 Diabetes and Defined Cardiovascular Risk

The current U.S. Trulicity label is centered on type 2 diabetes. It describes Trulicity as used with diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes mellitus.

The label also includes a cardiovascular-risk reduction indication. DailyMed states that Trulicity is indicated to reduce the risk of major adverse cardiovascular events, defined in the label as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.

That wording is worth preserving carefully. It is not a broad statement that dulaglutide prevents heart problems for everyone. It is not a product-selection recommendation. It is label context tied to adults with type 2 diabetes in defined cardiovascular-risk groups.

Lilly’s approval history helps explain why this wording appears in older and newer articles. Lilly announced Trulicity’s FDA approval in September 2014 as a once-weekly therapy for adults with type 2 diabetes. Lilly later announced, in February 2020, FDA approval of Trulicity for reducing major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.

The current label remains the primary source for the wording today.

5. Dulaglutide vs Liraglutide

Dulaglutide and liraglutide are different active ingredients. Both appear in GLP-1 receptor agonist discussions, but they point to different brand families and label histories.

Liraglutide is associated with Victoza and Saxenda. Current label sources describe Victoza and Saxenda as liraglutide products, while Trulicity is a dulaglutide product. That molecule difference matters even when public articles place all three names under a GLP-1 umbrella.

The frequency shorthand is also different in the labels reviewed here. Trulicity is described as once weekly. Victoza and Saxenda are described as once daily. That is a label fact, not a quality ranking and not a reason to infer that one product fits a particular person better than another.

For the molecule-level version of that comparison, see What Is Liraglutide?. For brand-specific context, see What Is Victoza? and What Is Saxenda?.

6. Dulaglutide vs Semaglutide

Dulaglutide and semaglutide are also different active ingredients. Trulicity contains dulaglutide. Ozempic, Wegovy, and Rybelsus are semaglutide brand contexts.

This distinction matters because semaglutide appears in multiple product forms and label contexts. Ozempic is centered on type 2 diabetes labeling, Wegovy is centered on weight-management and related labeled contexts, and Rybelsus is an oral semaglutide brand context for type 2 diabetes. Dulaglutide does not become semaglutide just because both names appear in GLP-1 articles.

A useful way to read comparison claims is to ask four questions before going further:

• Which active ingredient is being discussed?
• Which brand name is being discussed?
• Which current label source is being used?
• Is the article explaining names, or is it drifting into treatment advice?

For semaglutide-specific background, see What Is Semaglutide?.

7. Dulaglutide vs Tirzepatide

Dulaglutide and tirzepatide are different active ingredients with different receptor wording in current U.S. labels. Trulicity contains dulaglutide and is described as a GLP-1 receptor agonist. Mounjaro and Zepbound contain tirzepatide, and current tirzepatide labels describe it as a GIP and GLP-1 receptor agonist.

That receptor-language difference is often hidden by casual GLP-1 shorthand. People may place Trulicity, Ozempic, Wegovy, Mounjaro, and Zepbound in the same broad public conversation, but that does not make the molecules identical.

The clean comparison is factual:

This table does not rank products, compare outcomes, or suggest product choice. It only separates names that often get blurred together.

8. Why Dulaglutide Search Results Get Confusing

Dulaglutide search results get confusing because people often mix four question types into one search.

One question is about the molecule: “What is dulaglutide?” Another is about the brand: “Is dulaglutide Trulicity?” Another is about the class: “Is dulaglutide a GLP-1?” Another is medical: “Should someone start, stop, switch, or choose one medicine over another?”

This article answers only the first three at a high level. Dulaglutide is the active ingredient in Trulicity. Trulicity is a Lilly brand. Current U.S. label sources describe Trulicity as a once-weekly GLP-1 receptor agonist injection in type 2 diabetes and defined cardiovascular-risk contexts.

The fourth question is a treatment decision, not a dulaglutide definition. It needs more than the molecule, brand, and class facts this page is separating.

For recordkeeping, the safer habit is to log neutral facts separately: brand, active ingredient, route, source checked, date checked, and clinician notes. That is different from using a website to make a medication decision.

9. Sources

10. What Is Dulaglutide FAQ

• What is dulaglutide in simple terms?

  Dulaglutide is an active ingredient used in Trulicity, a prescription GLP-1 receptor agonist injection. Current U.S. label sources describe Trulicity as a once-weekly product used in type 2 diabetes and defined cardiovascular-risk contexts.

• Is dulaglutide the same as Trulicity?

  No. Dulaglutide is the active ingredient, while Trulicity is the Lilly brand name. The molecule and brand are closely related, but they are not the same kind of term.

• Is dulaglutide a GLP-1 receptor agonist?

  Yes. The current DailyMed label describes Trulicity, dulaglutide injection, as a glucagon-like peptide-1 receptor agonist. That class phrase is factual label context, not personal medical guidance.

• How is dulaglutide different from liraglutide, semaglutide, and tirzepatide?

  They are different active ingredients and brand families. Dulaglutide is associated with Trulicity, liraglutide with Victoza and Saxenda, semaglutide with Ozempic, Wegovy, and Rybelsus, and tirzepatide with Mounjaro and Zepbound. Tirzepatide labels also include GIP receptor language.